First Author: R.Kamal Salah SPAIN
Co Author(s): E. Jimenez Rodriguez P. Rivera de Zea 0 0 0 0 0 0 0 0 0
Back to previous
We present 7 patients diagnosed with cystoid macular edema (CME) secondary to noninfectious posterior uveitis (NIPU) treated with an intravitreal dexamethasone 0,7mg implant (OZURDEX®) to study its effectiveness and possible complications.
Hospital Virgen de la Victoria of Malaga (Spain)
We studied 7 eyes with CME secondary to different NIPU (sarcoidosis, Irvine-Gass síndrome, Birdshot desease and idiopathic uveítis), all of them treated with an OZURDEX®. They underwent a complete ocular examination including best corrected visual acuity (BCVA), intraocular pressure, biomicroscopy, funduscopy and optical coherence tomography using a macular cube 512x128 scan.
In most cases there was an improvement of the BCVA and the macular thickness in the first 30 days and they presented a deterioration between the days 90 and 180. One patient had an elevation of intraocular pressure (IOP) controlled with 1 IOP-lowering topical medication. A pseudophakic patient had a migration of the implant into the anterior chamber reposition was done without surgery. In another patient the implant was placed on the posterior side of the lens.
Ozurdex® has proven to be an effective treatment in CME secondary to noninfectious uveítis, specially in the first 4 months. The short term side effects are mainly elevation of IOP and the risks of intravitreal injections. There are other uncommon complications such as the migration of the implant to the anterior chamer or its placement in the posterior side of the lens. Further studies are needed to analyze theses uncommon complications and the long-term side effects.